Log in

NASDAQ:CERSCerus Stock Price, Forecast & News

$5.90
+0.05 (+0.85 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.72
Now: $5.90
$6.22
50-Day Range
$5.03
MA: $5.66
$6.41
52-Week Range
$2.71
Now: $5.90
$6.65
Volume2.00 million shs
Average Volume1.74 million shs
Market Capitalization$967.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Read More
Cerus logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.65 million
Book Value$0.41 per share

Profitability

Net Income$-71,240,000.00

Miscellaneous

Employees240
Market Cap$967.54 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Cerus (NASDAQ:CERS) Frequently Asked Questions

How has Cerus' stock been impacted by COVID-19 (Coronavirus)?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS stock has increased by 23.9% and is now trading at $5.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cerus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerus.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Cerus.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) released its earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.00. The biotechnology company had revenue of $18.61 million for the quarter, compared to analysts' expectations of $17.60 million. Cerus had a negative return on equity of 93.16% and a negative net margin of 90.97%. View Cerus' earnings history.

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $111.9 million.

What price target have analysts set for CERS?

3 Wall Street analysts have issued 1-year price targets for Cerus' shares. Their forecasts range from $6.50 to $8.00. On average, they expect Cerus' stock price to reach $7.17 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View analysts' price targets for Cerus.

Has Cerus been receiving favorable news coverage?

News stories about CERS stock have trended neutral this week, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerus earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutCerus.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.63%), Primecap Management Co. CA (6.83%), Nikko Asset Management Americas Inc. (6.53%), Nikko Asset Management Americas Inc. (6.53%), Sumitomo Mitsui Trust Holdings Inc. (6.52%) and State Street Corp (2.47%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View institutional ownership trends for Cerus.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Two Sigma Investments LP, Millrace Asset Group Inc., Primecap Management Co. CA, Morgan Stanley, Morgan Stanley, Baird Financial Group Inc., and Two Sigma Advisers LP. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman. View insider buying and selling activity for Cerus.

Which institutional investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including Silvercrest Asset Management Group LLC, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Sumitomo Mitsui Trust Holdings Inc., Paradigm Capital Management Inc. NY, First Midwest Bank Trust Division, and Geode Capital Management LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman. View insider buying and selling activity for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $5.90.

How big of a company is Cerus?

Cerus has a market capitalization of $967.54 million and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.